Clinical Trial Detail

NCT ID NCT03449108
Title Iovance Alliance: LN-145 Across Multiple Tumor Types
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

sarcoma

ovarian cancer

osteosarcoma

Therapies

Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna

Age Groups: adult child senior

No variant requirements are available.